Published in Clin Exp Metastasis on June 20, 2014
The thyroid hormone-αvβ3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation. Oncogene (2015) 0.83
CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS One (2016) 0.82
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells. Int J Mol Sci (2016) 0.78
SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. Oncogenesis (2016) 0.75
Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro. Oncotarget (2016) 0.75
Discover the molecular biomarker associated with cell death and extracellular matrix module in ovarian cancer. Biomed Res Int (2015) 0.75
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Biomarkers for epithelial-mesenchymal transitions. J Clin Invest (2009) 8.76
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev (2001) 5.09
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med (2009) 3.05
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther (2004) 2.17
Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol (2006) 2.06
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res (1985) 2.06
Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol (2007) 1.97
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer (2013) 1.93
Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets (2010) 1.91
Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol (2009) 1.82
The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol (2002) 1.73
Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res (2005) 1.69
Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis (2008) 1.65
The morphological and molecular features of the epithelial-to-mesenchymal transition. Nat Protoc (2009) 1.60
An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis (2013) 1.49
MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene (2010) 1.48
Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia (2007) 1.45
Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med (2006) 1.43
alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene (2003) 1.36
Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One (2012) 1.31
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia (2008) 1.29
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol (2013) 1.29
Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res (1999) 1.28
Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res (2012) 1.28
Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene (2010) 1.26
Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer (1994) 1.24
Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev (2014) 1.14
Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer (2005) 1.13
Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res (1987) 1.12
aV integrins and TGF-β-induced EMT: a circle of regulation. J Cell Mol Med (2012) 1.07
Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol (2012) 1.07
Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Int J Cancer (2005) 1.05
Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. Tumour Biol (2008) 1.03
Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett (2008) 1.00
Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. Exp Cell Res (2013) 0.97
Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer (2007) 0.95
Migration properties of the human ovarian adenocarcinoma cell line IGROV1: importance of alpha(v)beta3 integrins and vitronectin. Int J Cancer (1999) 0.94
The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. Virchows Arch (2011) 0.93
Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway? Cancer Metastasis Rev (2003) 0.90
Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer (2011) 0.89
Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol (2006) 0.87
Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression. Gynecol Oncol (2007) 0.85
Ovarian cancer ascites-derived vitronectin and fibronectin: combined purification, molecular features and effects on cell response. Biochim Biophys Acta (2013) 0.83
Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer (2012) 0.83
Spontaneous spheroid budding from monolayers: a potential contribution to ovarian cancer dissemination. Biol Open (2012) 0.82
Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol (2006) 0.82
Epithelial-mesenchymal transition enhances nanoscale actin filament dynamics of ovarian cancer cells. J Phys Chem B (2013) 0.81
Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin. Tumour Biol (2010) 0.81
Regulation of adhesion site dynamics by integrin traffic. Curr Opin Cell Biol (2012) 0.81
Integrin αvβ3 promotes vitronectin gene expression in human ovarian cancer cells by implicating rel transcription factors. J Cell Biochem (2011) 0.80
Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. Curr Opin Obstet Gynecol (1999) 0.75
Plasma membrane vesicles from source and sink leaves : changes in solute transport and polypeptide composition. Plant Physiol (1992) 1.19
The sucrose carrier of the plant plasmalemma. III. Partial purification and reconstitution of active sucrose transport in liposomes. Biochim Biophys Acta (1992) 1.06
Reconstitution of active sucrose transport in plant proteoliposomes. FEBS Lett (1991) 0.99
Identification of proteins undergoing expression level modifications in WI-38 SV40 fibroblasts overexpressing methionine sulfoxide reductase A. Biochimie (2007) 0.92
Sulfur dioxide inhibits the sucrose carrier of the plant plasma membrane. Biochim Biophys Acta (1992) 0.92
Plasma fibronectin: three steps to purification and stability. Protein Expr Purif (1999) 0.88
Physico-chemical characteristics and protein adsorption potential of hydroxyapatite particles: influence on in vitro biocompatibility of ceramics after sintering. Colloids Surf B Biointerfaces (2006) 0.87
[Chronic hypoparathyroidism: review of 5 clinical cases]. Acta Med Port (1991) 0.78
Rapid and soft formulation of folate-functionalized nanoparticles for the targeted delivery of tripentone in ovarian carcinoma. Int J Pharm (2013) 0.78
Proteolysis of aggregated fibronectin. A model for in vivo matrix degradation. Ann N Y Acad Sci (1998) 0.77
Fibronectin layers by matrix-assisted pulsed laser evaporation from saline buffer-based cryogenic targets. Acta Biomater (2011) 0.76
Psychoneuroendocrine characteristics of common obesity clinical subtypes. Int J Obes Relat Metab Disord (2001) 0.76
Diabetic retinopathy in a population of 1,302 insulin dependent diabetics (IDDM) diagnosed before 30 years of age. Int Ophthalmol (1992) 0.75
[Use of photogrammetry for taking body contours in radiotherapy]. J Radiol Electrol Med Nucl (1975) 0.75
Transient hyperandrogenemia and its relation to ovulation. Fertil Steril (1998) 0.75
[Evolution of a population of insulin-dependent diabetics. 55 years' experience in a diabetology practice]. Journ Annu Diabetol Hotel Dieu (1982) 0.75
Dyslipidaemia in female overweight and obese patients. Relation to anthropometric and endocrine factors. Int J Obes Relat Metab Disord (1998) 0.75
Stopping biguanide therapy. Lancet (1980) 0.75
[Interactions of the Pseudomonas aeruginosa outer membrane proteins with plasma fibronectins. Bacterial adhesin investigation]. C R Acad Sci III (1999) 0.75
Synthesis and cytotoxic activity against L1210 leukemia of new aminocyclopenta[c]thiophenones. Chem Pharm Bull (Tokyo) (1994) 0.75
Fabrication of functional fibronectin patterns by nanosecond excimer laser direct write for tissue engineering applications. J Mater Sci Mater Med (2013) 0.75
Transient amidolytic activity changes of plasmin adsorbed onto carbons. Biomol Eng (2002) 0.75